AFAMITRESGENE AUTOLEUCEL
UNII CUY18BJ7BP

Substance Identification & Data

This profile provides standardized clinical and technical data for Afamitresgene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CUY18BJ7BP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CUY18BJ7BP

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

AFAMITRESGENE AUTOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

CUY18BJ7BP

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C175738

National Cancer Institute reference terminology for clinical and research data.

INN ID

11286

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-54

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Afamitresgene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

AFAMITRESGENE AUTOLEUCEL

Common Names & Synonyms

AFAMITRESGENE AUTOLEUCEL [INN]

AFAMITRESGENE AUTOLEUCEL [USAN]

AFAMITRESGENE AUTOLEUCEL [WHO-DD]

AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, ANTIGEN MAGE A4) HLA-A*02 PEPTIDE DRIVEN BY THE ELONGATION FACTOR 1 ALPHA (EF1.ALPHA.) PROMOTER. CELLS EXPRESS LYMPHONODE-HOMING MARKERS CCR7 AND CD62L, CD45 ISOFORMS CD45RA AND CD45R0, CO-STIMULATORY MARKERS CD27 AND CD28, IL-7 RECEPTOR CD127, AND CHEMOKINE RECEPTOR CXCR3. CELLS SECRETE INTERLEUKIN 2 (IL-2), TUMOR NECROSIS FACTOR (TNF-ALPHA, TNF.ALPHA.), INTERFERON GAMMA (INTERFERON .GAMMA., IFN-GAMMA), GRANZYME, INTERLEUKIN 4 (IL-4), INTERLEUKIN 13 (IL-13) AND INTERLEUKIN 17 (IL-17) UPON ACTIVATION